Sana director Hans Bishop gets 6,157 shares
Sana Biotechnology director Hans Edgar Bishop reported an equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sana Biotechnology director Hans Edgar Bishop reported an equity award. On January 5, 2026, he acquired 6,157 shares of Common Stock in a transaction coded "A" for acquisition. The footnote explains these consist of fully vested restricted stock units, with a reported price of $0.00 per share, indicating no cash purchase. After this grant, Bishop is shown as beneficially owning 5,840,740 shares of Sana Biotechnology common stock in direct ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 6,157 | $0.00 | $0.00 |
Footnotes (1)
- F1. Consists of fully vested restricted stock units.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sana Biotechnology (SANA) report for Hans Edgar Bishop?
The filing reports that director Hans Edgar Bishop acquired 6,157 shares of Common Stock on January 5, 2026 in a transaction coded as an acquisition.
What is Hans Edgar Bishop’s relationship to Sana Biotechnology (SANA)?
Hans Edgar Bishop is identified in the filing as a director of Sana Biotechnology, Inc. and is not listed as an officer or 10% owner.
Was the Sana Biotechnology (SANA) Form 4 filed for one or multiple reporting persons?
The Form 4 indicates it is filed by one reporting person, namely Hans Edgar Bishop, with the signature provided by an attorney-in-fact.
AI-generated analysis. How Rhea-AI works. Not financial advice.